Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 307
- Registration Number
- NCT02604823
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1711
- Registration Number
- NCT02604836
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients
- Conditions
- Hepatitis B, Chronic
- Interventions
- Other: Matching PlaceboDrug: RO7020322
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT02604355
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Grafton, New Zealand
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇳🇿Tauranga Hospital, Tauranga, New Zealand
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT02600897
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom
🇬🇧Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom
🇬🇧Barking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital, Romford, United Kingdom
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: ACCU-CHEK
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT02600845
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 308
- Registration Number
- NCT02598934
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 545
- Registration Number
- NCT02598453
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT02598440
Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 89
- Registration Number
- NCT02598193
- Locations
- 🇺🇸
Stanford University School of Medicine ; Pulmonary/Critical Care Medicine, Stanford, California, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
🇺🇸Inova Health Care Services; Advanced Lung Disease Transplant Program, Falls Church, Virginia, United States
Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 223
- Registration Number
- NCT02598167
- Locations
- 🇪🇸
Hospital Sant Joan Despi Moises Broggi; Servicio de Neurología, Sant Joan Despí, Barcelona, Spain
🇪🇸Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, Spain
🇪🇸Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain